Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
12.54
+0.32 (2.62%)
Nov 22, 2024, 4:00 PM EST - Market closed
Cullinan Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | - | - | - | 18.94 | - | - | Upgrade
|
| Gross Profit | - | - | - | 18.94 | - | - | Upgrade
|
| Selling, General & Admin | 50.1 | 42.49 | 40.19 | 29.15 | 17.12 | 5.48 | Upgrade
|
| Research & Development | 137.26 | 148.16 | 91.95 | 57.75 | 43.21 | 16.79 | Upgrade
|
| Operating Expenses | 187.36 | 190.65 | 132.14 | 86.9 | 60.34 | 22.27 | Upgrade
|
| Operating Income | -187.36 | -190.65 | -132.14 | -67.95 | -60.34 | -22.27 | Upgrade
|
| Interest & Investment Income | 28.07 | 21.63 | 6.61 | 0.48 | 0.89 | 0.62 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.32 | 0.24 | 0.06 | -0.01 | -0.01 | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -159.61 | -168.78 | -125.47 | -67.49 | -59.46 | -21.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 276.79 | - | - | - | Upgrade
|
| Asset Writedown | - | -0.44 | - | - | - | - | Upgrade
|
| Pretax Income | -159.61 | -169.22 | 151.32 | -67.49 | -59.46 | -21.65 | Upgrade
|
| Income Tax Expense | -14.12 | -14.12 | 42.12 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -145.49 | -155.1 | 109.2 | -67.49 | -59.46 | -21.65 | Upgrade
|
| Minority Interest in Earnings | 1.95 | 1.94 | 2.02 | 1.92 | 7.66 | 1 | Upgrade
|
| Net Income | -143.54 | -153.16 | 111.21 | -65.57 | -51.8 | -20.66 | Upgrade
|
| Net Income to Common | -143.54 | -153.16 | 111.21 | -65.57 | -51.8 | -20.66 | Upgrade
|
| Shares Outstanding (Basic) | 50 | 42 | 45 | 43 | 20 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 50 | 42 | 47 | 43 | 20 | 1 | Upgrade
|
| Shares Change (YoY) | 17.81% | -10.91% | 8.27% | 116.61% | 2088.17% | 150.89% | Upgrade
|
| EPS (Basic) | -2.88 | -3.69 | 2.46 | -1.52 | -2.60 | -22.73 | Upgrade
|
| EPS (Diluted) | -2.88 | -3.69 | 2.38 | -1.52 | -2.60 | -22.73 | Upgrade
|
| Free Cash Flow | -126.81 | -134.48 | -127.8 | -43.43 | -29.78 | -20.92 | Upgrade
|
| Free Cash Flow Per Share | -2.55 | -3.24 | -2.74 | -1.01 | -1.50 | -23.01 | Upgrade
|
| Gross Margin | - | - | - | 100.00% | - | - | Upgrade
|
| Operating Margin | - | - | - | -358.73% | - | - | Upgrade
|
| Profit Margin | - | - | - | -346.14% | - | - | Upgrade
|
| Free Cash Flow Margin | - | - | - | -229.28% | - | - | Upgrade
|
| EBITDA | -187.05 | -190.34 | -132.04 | -67.9 | -60.27 | -22.2 | Upgrade
|
| D&A For EBITDA | 0.31 | 0.31 | 0.09 | 0.05 | 0.06 | 0.07 | Upgrade
|
| EBIT | -187.36 | -190.65 | -132.14 | -67.95 | -60.34 | -22.27 | Upgrade
|
| Effective Tax Rate | - | - | 27.84% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.